Simulating drug penetration during hyperthermic intraperitoneal chemotherapy
Hyperthermic intraperitoneal chemotherapy (HIPEC) is administered to treat residual microscopic disease after debulking cytoreductive surgery. During HIPEC, a limited number of catheters are used to administer and drain fluid containing chemotherapy (41-43 °C), yielding heterogeneities in the perito...
Saved in:
Main Authors: | Daan R. Löke (Author), Roxan F. C. P. A. Helderman (Author), Nicolaas A. P. Franken (Author), Arlene L. Oei (Author), Pieter J. Tanis (Author), Johannes Crezee (Author), H. Petra Kok (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anesthetic implications in hyperthermic intraperitoneal chemotherapy
by: Nishkarsh Gupta, et al.
Published: (2019) -
Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer
by: V. V. Saevets, et al.
Published: (2022) -
The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
by: Kate Glennon, et al.
Published: (2021) -
Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
by: Jieun Ko, et al.
Published: (2021) -
Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer
by: Laura M. Chambers, et al.
Published: (2022)